Last reviewed · How we verify
Antibiotic-Cefamezin
At a glance
| Generic name | Antibiotic-Cefamezin |
|---|---|
| Also known as | Ceforal, Keflex |
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Antibiotics for Prevention of Infection Following Orthognathic Surgery (PHASE4)
- Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic (NA)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (PHASE2)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Local Antibiotics for Breast Implants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antibiotic-Cefamezin CI brief — competitive landscape report
- Antibiotic-Cefamezin updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI